Daiichi Sankyo Company, Limited (4568.T)
Tokyo - Tokyo Delayed price. Currency in JPY
Add to watchlist
At close: 03:15PM JST
| Previous close | 5,198.00 |
| Open | 5,293.00 |
| Bid | 5,382.00 x N/A |
| Ask | 5,390.00 x N/A |
| Day's range | 5,243.00 - 5,389.00 |
| 52-week range | 3,566.00 - 5,520.00 |
| Volume | |
| Avg. volume | 4,365,437 |
| Market cap | 10.326T |
| Beta (5Y monthly) | 0.26 |
| PE ratio (TTM) | 51.54 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 60.00 (1.15%) |
| Ex-dividend date | 27 Sept 2024 |
| 1y target est | N/A |
- Benzinga
Heart Disease Drugmaker Esperion Therapeutics Reports Highest Revenue Yet, Stock Soars
Tuesday, Esperion Therapeutics (NASDAQ:ESPR) reported first-quarter revenues of $137.74 million, up 467% Y/Y, surpassing the consensus of $84.51 million. The company reported an EPS of $0.34, a turnaround from an EPS loss of $(0.79) a year ago, beating the consensus of $0.05. U.S. net product revenue was $24.8 million, up approximately 46% Y/Y. Collaboration revenue was $113.0 million, compared to $7.3 million a year ago, driven by increased tablet sales to international partners and sales growt
- Yahoo Finance
AstraZeneca CEO on US-China tensions: 'We have established a very resilient supply chain'
AstraZeneca CEO Pascal Soriot joined Yahoo Finance to discuss the company's earnings today.
- Zacks
Atossa (ATOS) Reports Positive Results From EVANGELINE Study
Atossa (ATOS) unveils positive results from its phase 2 EVANGELINE clinical study, which shows that (Z)-endoxifen can reduce the growth of ER+ breast cancer.
© 2024 Yahoo. All rights reserved.